Antiplatelet therapy in the elderly: Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists

David C. Calverley

    Research output: Contribution to journalArticlepeer-review

    11 Scopus citations


    Antiplatelet agents including aspirin, dipyridamole, the thienopyridines, and the GPIIb/IIla antagonists have collectively demonstrated their ability to have a significant impact on the incidence of recurrent MIs, strokes, and other vascular ischemic events in the geriatric population. Low-dose aspirin also seems to be effective and safe for the primary prevention of ischemic heart disease in men considered at high risk. There is no evidence that the recommendations from these studies had increased relevance to younger adults, and the studies considering age as a variable found antiplatelet agents had either similar or increased benefit in older patients. In view of the relatively reduced adverse effects of these agents when compared with their potential therapeutic benefit, it is important that they be considered in all older patients for secondary prevention and in certain high-risk groups for primary prevention of cardiovascular morbidity and mortality.

    Original languageEnglish (US)
    Pages (from-to)31-48
    Number of pages18
    JournalClinics in Geriatric Medicine
    Issue number1
    StatePublished - 2001

    ASJC Scopus subject areas

    • Geriatrics and Gerontology


    Dive into the research topics of 'Antiplatelet therapy in the elderly: Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists'. Together they form a unique fingerprint.

    Cite this